Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mercury BiopharmaceuticalROCO:6932 +0.89%25 Buyback Yield % is 0.17 as of Jul. 22, 2026, which is 240% above its 10-year median of 0.05. GuruFocus rates ROCO:6932 with a GF Score™ of 25/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 291 Drug Manufacturers companies, Mercury Biopharmaceutical ranks better than 73.2% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6932 vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Biopharmaceutical Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Mercury Biopharmaceutical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mercury Biopharmaceutical (ROCO:6932) has a Buyback Yield % of 0.17 as of Jul. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mercury Biopharmaceutical and its competitors. This is 240% above median its historical median of 0.05. According to the industry distribution chart, Mercury Biopharmaceutical ranks #78 out of 291 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is Mercury Biopharmaceutical's Buyback Yield % too high?
Mercury Biopharmaceutical's current Buyback Yield % of 0.17 is 240% above median its 10-year median of 0.05. Based on the distribution chart, Mercury Biopharmaceutical ranks #78 out of 291 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mercury Biopharmaceutical ranks #78 out of 291 companies for Buyback Yield %. This puts Mercury Biopharmaceutical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mercury Biopharmaceutical and its competitors. Mercury Biopharmaceutical's current Buyback Yield % is 0.17, which is 240% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.69 — trading 84.2% below its estimated fair value. The current Buyback Yield % is 0.17, which is 240% above median its 10-year median of 0.05. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Buyback Yield % is 0.17 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued.
The current stock price of NT$5.69 is trading 84.2% below its estimated GF Value™ of NT$36.00.
GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:6932:
Buyback Yield %: 0.17 (240% above median its 10-year median of 0.05)
GF Value™: NT$36.00 vs. price of NT$5.69 (84.2% below fair value)
No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score
Get the complete analysis for ROCO:6932
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6932 has been successfully added to your 
